Actualités et vidéos - ENTEST BIOMEDICAL

Entest Group, Inc. Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc. PR Newswire SAN DIEGO, May 10, 2018 SAN DIEGO , May 10, 2018 /PRNewswire/ -- On May 10, 2018 , Entest Group, Inc. (OTC: ETNI) declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001 , currently owned by Entest Group, Inc. to: (a) Holders of record of the outstanding common shares of ETNI as of the record...

Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders Dividend is Approximately 83% Payout of Zander's Issued and Outstanding Common Shares PR Newswire SAN DIEGO, September 29, 2017 SAN DIEGO , September 29, 2017 /PRNewswire/ -- Entest BioMedical, Inc. (OTC:ENTB) today announced that its Board of Directors has authorized a distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc....

Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board PR Newswire SAN DIEGO, September 13, 2017 SAN DIEGO , September 13, 2017 /PRNewswire/ -- Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) announced the appointment of Robin Beat Gasser , DVM, Ph.D. as a Senior Veterinarian Advisor to the Company. Dr. Gasser is among the world's most recognized parasite biologists and is Professor of Parasitology and Director of...

Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators PR Newswire SAN DIEGO, July 26, 2017 SAN DIEGO , July 26, 2017 /PRNewswire/ -- Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) reported that researchers for Regen BioPharma Inc. have identified what the company believes to be a strong activator for modulating checkpoint NR2F6. This is significant to Zander Therapeutics for...

Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine Studies Company sees results demonstrating a major step forward in its small molecule anti-inflammatory drug development for veterinary use PR Newswire SAN DIEGO, June 13, 2017 SAN DIEGO , June 13, 2017 /PRNewswire/ -- Entest BioMedical Inc.'s (OTC-PINK: ENTB) subsidiary, Zander Therapeutics, Inc....

Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds PR Newswire SAN DIEGO, June 7, 2017 SAN DIEGO , June 7, 2017 /PRNewswire/ -- Entest BioMedical Inc.'s (PINK: ENTB) subsidiary, Zander Therapeutics Inc. ,reported that initial data from its canine study suggest that compounds currently being tested ex vivo show promise as small molecule anti-inflammatory treatments in canines. The Company is in the...

Entest BioMedical, Inc. Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities Company views debt settlement as a positive step in cleaning up balance sheet PR Newswire SAN DIEGO, May 31, 2017 SAN DIEGO , May 31, 2017 /PRNewswire/ -- Entest BioMedical Inc. (PINK: ENTB) announced today that it has satisfied $841,531 of Notes Payable as well as $83,000 of accrued expenses through the issuance of the Company's non-voting convertible preferred stock to the creditors....

Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary Applications of Cancer and Autoimmune Therapies Through Modulation of Checkpoint NR2F6 Advanced studies demonstrate key structure in modulation of NR2F6 PR Newswire SAN DIEGO, May 23, 2017 SAN DIEGO , May 23, 2017 /PRNewswire/ -- Entest BioMedical Inc. (PINK: ENTB) and Its subsidiary, Zander Therapeutics Inc., discussed recently reported progress achieved by Regen BioPharma Inc....

Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs Company is focused on small molecule modulation of Checkpoint NR2F6 PR Newswire SAN DIEGO, April 26, 2017 SAN DIEGO , April 26, 2017 /PRNewswire/ -- Entest BioMedical Inc.'s (OTCPINK: ENTB) Chairman and CEO David Koos discussed current and anticipated developments for the company's subsidiary, Zander Therapeutics Inc....

Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies on Modulating NR2F6 in Canines PR Newswire SAN DIEGO, April 19, 2017 SAN DIEGO , April 19, 2017 /PRNewswire/ -- Entest BioMedical Inc.'s (OTCPINK: ENTB) subsidiary, Zander Therapeutics, Inc., has contracted with ChemDiv, Inc., an internationally recognized contract research organization, to test certain NR2F6 modulators licensed to Zander Therapeutics by Regen BioPharma in a cellular system. Specifically, the...

Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor PR Newswire SAN DIEGO, March 9, 2017 SAN DIEGO , March 9, 2017 /PRNewswire/ -- Dr. Donnelly is an I nternational ly Recognized Animal Researcher, who the Company Believes Will Play an Important Role in the Development of Zander ' s NR2F6 Small Molecule Drug Development Program for Veterinary Applications in Treating Canine Cancer and Arthritis in Animals...

Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs PR Newswire SAN DIEGO, February 15, 2017 SAN DIEGO , February 15, 2017 /PRNewswire/ -- Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, Zander Therapeutics Inc., announced today publication by the United States Patent and Trademark Office of a Utility Patent application entitled "Canine Autologous Immunotherapy using Dendritic...

Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche PR Newswire SAN DIEGO, February 6, 2017 SAN DIEGO , February 6, 2017 /PRNewswire/ -- Zander Prepares to Move Forward With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which Include Arthritis Entest BioMedical Inc.'s (OTCPINK: ENTB) Zander Therapeutics...

Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses Company Initiates Program to Leverage Activators of its Proprietary NR2F6 Target to Treat Exercise Induced Pulmonary Hypertension PR Newswire SAN DIEGO, January 10, 2017 SAN DIEGO , January 10, 2017 /PRNewswire/ -- Entest BioMedical Inc. (OTCPINK: ENTB) announced today that its wholly...

Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017 PR Newswire SAN DIEGO, December 21, 2016 SAN DIEGO , December 21, 2016 /PRNewswire/ -- Entest BioMedical, Inc. (PINKS: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for Zander Therapeutics, Inc., the Company's wholly owned subsidiary. "Zander Therapeutics Inc. is committed to moving forward with regards to the development...

Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications PR Newswire SAN DIEGO, October 19, 2016 SAN DIEGO , October 19, 2016 /PRNewswire/ -- A Potential Treatment for Cancer and Arthritis in Animals Entest BioMedical's (OTCPINK: ENTB) wholly owned subsidiary Zander Therapeutics, Inc. announced the filing of a patent application covering composition of matter and methods of use related to molecules...